John Burke, MD, Discuses the Rationale for Examining Pembrolizumab in High-Risk RCC After Surgery

Article

CancerNetwork®sat down with John Burke, MD, to discuss why treatment with pembrolizumab post-surgery may be a promising option for patients with high-risk renal cell carcinoma.

John Burke, MD, a heamtologist and medical oncologist from Rocky Mountain Cancer Centers, spoke with CancerNetwork® about the reasoning behind the phase 3 KEYNOTE-564 study (NCT03142334), assessing pembrolizumab (Keytruda) in a population of patients with high-risk renal cell carcinoma (RCC) following surgery. Notably, several different drugs have already been examined in this patient population, which have yielded poor results. However, treatment with pembrolizumab appeared promising, due to its ability to aid patients’ immune ability in fighting off cancer.

Transcript:

After surgical removal of the kidney, there's a possibility that the cancer will still relapse and that risk is higher for patients with larger tumors, or whose tumors are invading into the vein or who have lymph node involvement around the kidney; the risk is higher of having a recurrence.

Historically, a number of drugs have been tried to reduce the risk of kidney cancer recurrence after surgery, like we do with many other cancers like breast and colon cancer. None of them have really worked with 1 exception, which is sunitinib [Sutent], which a few years ago was shown to be able to reduce the risk of recurrence but the benefit was pretty small, and the toxicities of sunitinib are quite significant. It took a long time for those [who] benefited to be evident. This was considered an area of need, where it was a goal to try to find a treatment that would be able to reduce the risk of relapse of kidney cancer after surgery.

That brings us to the drug that we studied in this trial, pembrolizumab, [which] is a monoclonal antibody that targets PD-1. Using pembrolizumab basically is improving the patient’s immune system's ability to attack the cancer cells. It's really a way of driving the patient's own immune system to attack cancer cells. We know that pembrolizumab is an effective treatment for patients with kidney cancer that has spread to other parts of the body, as well as many other cancers that have spread to other parts of the body.

Reference

Choueiri TK, Tomczak P, Park SH, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: randomized, double-blind, phase III KEYNOTE-564 study. J Clin Oncol. 2021;39(suppl 18). doi:10.1200/JCO.2021.39.15_suppl.LBA5

Recent Videos
A review of patients with metastatic clear cell renal cell carcinoma shows radiological tumor burden as an independent prognostic factor for survival.
A phase 2 trial is assessing ubamatamab in patients with MUC16-expressing SMARCB1-deficient renal medullary carcinoma and epithelioid sarcoma.
Analysis of 2 phase 1 trials compared gut biome diversity between standard of care with or without CBM588 in patients with metastatic renal cell carcinoma.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Rohit Gosain, MD; Sumanta Kumar Pal, MD, FASCO; and Rahul Gosain, MD, presenting slides
Related Content